# Creating Efficiency in Foreign Facility Inspections Act

This bill streamlines how the federal government inspects foreign facilities that produce food, drugs, and medical devices for the American market. Right now, the FDA has to send inspectors to these facilities around the world to make sure products meet U.S. safety standards before they're shipped to stores and hospitals here. The bill makes this process faster and more efficient by allowing the FDA to use alternative inspection methods and reduce some of the paperwork and bureaucratic steps involved.

The main change is that the bill gives the FDA more flexibility in how it conducts these inspections. Instead of always sending inspectors in person, the agency can use remote inspections, third-party inspectors, or other methods when appropriate. This could speed up the inspection process and reduce costs, which might help get safe products to market faster. The bill also simplifies some of the requirements foreign facilities have to meet when dealing with U.S. regulators, making it less burdensome for companies that want to export to America.

For everyday people, this could mean faster access to imported medicines, food products, and medical devices. However, the trade-off is that some worry less frequent in-person inspections might make it harder to catch safety problems. The bill aims to balance efficiency with safety by allowing the FDA to still conduct thorough inspections, just in a more streamlined way. Overall, this is a relatively technical change focused on making government operations more efficient rather than changing what products are allowed or how safe they need to be.

Creating Efficiency in Foreign Facility Inspections Act

Braun, Mike

Creating Efficiency in Foreign Facility Inspections Act This bill prohibits, with some exceptions, the Food and Drug Administration (FDA) from providing notification in advance of a planned inspection of an establishment located outside of the United States that is engaged in drug manufacturing, processing, packing, or holding. Specifically, the FDA may not provide such an establishment advance notification of a planned inspection unless (1) advance notification is required by the laws of the country where the establishment is located; (2) providing advance notification is needed to protect the public health; or (3) the inspection in question is a preapproval, prelicensure, or for-cause inspection. If the FDA must provide advance notification, it must minimize the time between the notification and the inspection. If an establishment is located in a country that, on or after the date this bill is enacted, enacts a law requiring advance notification of inspections, the drug manufacturer must agree to waive the right to enforce the requirement, to the extent expressly permitted by the law.